A detailed history of Charles Schwab Investment Management Inc transactions in Aura Biosciences, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 138,356 shares of AURA stock, worth $1.26 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
138,356
Previous 134,744 2.68%
Holding current value
$1.26 Million
Previous $1.02 Million 21.02%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$6.9 - $10.36 $24,922 - $37,420
3,612 Added 2.68%
138,356 $1.23 Million
Q2 2024

Aug 12, 2024

BUY
$6.81 - $7.89 $194,085 - $224,865
28,500 Added 26.83%
134,744 $1.02 Million
Q1 2024

May 08, 2024

BUY
$7.09 - $9.24 $104,903 - $136,715
14,796 Added 16.18%
106,244 $834,000
Q4 2023

Feb 06, 2024

BUY
$7.02 - $11.98 $131,449 - $224,325
18,725 Added 25.75%
91,448 $810,000
Q2 2023

Aug 09, 2023

BUY
$8.51 - $13.33 $79,228 - $124,102
9,310 Added 14.68%
72,723 $898,000
Q1 2023

May 11, 2023

BUY
$8.88 - $12.11 $138,581 - $188,988
15,606 Added 32.64%
63,413 $588,000
Q4 2022

Feb 13, 2023

BUY
$9.86 - $14.59 $7,927 - $11,730
804 Added 1.71%
47,807 $501,000
Q3 2022

Nov 14, 2022

BUY
$13.1 - $20.34 $52,321 - $81,237
3,994 Added 9.29%
47,003 $852,000
Q2 2022

Aug 15, 2022

BUY
$12.37 - $21.86 $341,783 - $603,991
27,630 Added 179.66%
43,009 $610,000
Q1 2022

May 13, 2022

BUY
$15.94 - $23.34 $56,698 - $83,020
3,557 Added 30.09%
15,379 $339,000
Q4 2021

Feb 11, 2022

BUY
$14.76 - $24.89 $174,492 - $294,249
11,822 New
11,822 $201,000

Others Institutions Holding AURA

About Aura Biosciences, Inc.


  • Ticker AURA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 29,273,600
  • Market Cap $268M
  • Description
  • Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develop...
More about AURA
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.